{"id":"butamben","rwe":[{"pmid":"40465558","year":"2025","title":"Engaging hydrazine hydrate as a hydrogen source for cobalt(II)-catalysed transfer hydrogenation of nitroaromatics.","finding":"","journal":"Chemical communications (Cambridge, England)","studyType":"Clinical Study"},{"pmid":"39725929","year":"2024","title":"Evaluating the effectiveness of advanced platelet-rich fibrin, photobiomodulation, pentoxifylline, and Alveogyl in the treatment of alveolar osteitis: a randomized controlled clinical trial.","finding":"","journal":"BMC oral health","studyType":"Clinical Study"},{"pmid":"39582403","year":"2025","title":"Novel topical dressing for dry socket and comparison of its efficacy with that of Alvogyl®: A randomized controlled clinical trial.","finding":"","journal":"Medicina oral, patologia oral y cirugia bucal","studyType":"Clinical Study"},{"pmid":"39530606","year":"2024","title":"Low-level laser treatment's ability to reduce dry socket pain.","finding":"","journal":"Acta odontologica Scandinavica","studyType":"Clinical Study"},{"pmid":"39065560","year":"2024","title":"Development of a Versatile Nanostructured Lipid Carrier (NLC) Using Design of Experiments (DoE)-Part II: Incorporation and Stability of Butamben with Different Surfactants.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"}],"_fda":{"id":"66344c64-2439-4a34-8eb4-707e707c8ab1","set_id":"89f262a4-a41b-41d7-806b-61b9b89542f0","openfda":{"nui":["N0000185508","N0000175629","N0000184306","M0000728"],"unii":["U3RSY48JW5","EFW857872Q","5NF5D4OPCI"],"route":["TOPICAL"],"rxcui":["543786","543789"],"spl_id":["66344c64-2439-4a34-8eb4-707e707c8ab1"],"brand_name":["Cetacaine Anesthetic"],"spl_set_id":["89f262a4-a41b-41d7-806b-61b9b89542f0"],"package_ndc":["10223-0202-2","10223-0202-4","10223-0202-5","10223-0202-6","10223-0202-7","10223-0202-8","10223-0225-1","10223-0226-1"],"product_ndc":["10223-0202","10223-0225","10223-0226"],"generic_name":["BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Allergens [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]"],"substance_name":["BENZOCAINE","BUTAMBEN","TETRACAINE HYDROCHLORIDE"],"pharm_class_epc":["Standardized Chemical Allergen [EPC]"],"manufacturer_name":["Cetylite Industries, Inc."],"is_original_packager":[true]},"version":"9","warnings":["WARNINGS AND PRECAUTIONS Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Cetacaine and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen."],"pregnancy":["Use in Pregnancy Safe use of Cetacaine has not been established with respect to possible adverse effects upon fetal development. Therefore, Cetacaine should not be used during early pregnancy, unless in the judgement of a physician, the potential benefits outweigh the unknown hazards. Routine precaution for the use of any topical anesthetic should be observed when Cetacaine is used."],"how_supplied":["How Supplied Cetacaine Spray, 20 g bottle, including propellant WARNING Cetacaine Spray contains CFC-114 and CFC-11, substances which harm public health and environment by destroying ozone in the upper atmosphere. The propellant leak rate of Cetacaine Spray does not meet the USP requirements. (Item # 0220, NDC 10223-0201-3) which includes one cannula. Cetacaine Spray Single Patient Use, 5 g bottle, including propellant (Item # 0222, NDC 10223-0201-4) which includes one cannula. Cetacaine Liquid Chairside Kit (Item # 0218 NDC 10223-0202-6) which includes one 14 g bottle of Cetacaine Liquid with Luer-lock dispenser cap, 20 syringes and 20 delivery tips. Cetacaine Liquid Clinical Kit (Item # 0212, NDC 10223-0202-5) which includes one 30 g bottle of Cetacaine Liquid with Luer-lock dispenser cap, 100 syringes and 100 delivery tips. Cetacaine Liquid, 14 g bottle (Item # 0203, NDC 10223-0202-2) with Luer-lock dispenser cap. Cetacaine Liquid, 30 g bottle (Item # 0211, NDC 10223-0202-4) with Luer-lock dispenser cap."],"effective_time":"20250110","contraindications":["Contraindications Do not use Cetacaine Spray or Cetacaine Liquid to treat infants or children younger than 2 years. Cetacaine is not suitable and should never be used for injection. Do not use on the eyes. To avoid excessive systemic absorption, Cetacaine should not be applied to large areas of denuded or inflamed tissue. Cetacaine should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. Tolerance may vary with the status of the patient. Cetacaine should not be used under dentures or cotton rolls, as retention of the active ingredients under a denture or cotton roll could possibly cause an escharotic effect. Routine precaution for the use of any topical anesthetic should be observed when using Cetacaine."],"drug_interactions":["DRUG INTERACTIONS Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents: Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine"],"mechanism_of_action":["Action The onset of Cetacaine-produced anesthesia is rapid (approximately 30 seconds) and the duration of anesthesia is typically 30-60 minutes, when used as directed. This effect is due to the rapid onset, but short duration of action of Benzocaine coupled with the slow onset, but extended duration of Tetracaine HCI and bridged by the intermediate action of Butamben. These agents act by reversibly blocking nerve conduction. Speed and duration of action is determined by the ability of the agent to be absorbed by the mucous membrane and nerve sheath and then to diffuse out, and ultimately be metabolized (primarily by plasma cholinesterases) to inert metabolites which are excreted in the urine."],"storage_and_handling":["Store at controlled room temperature 20-25°C (68-77°F)"],"indications_and_usage":["Indications Cetacaine is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. Cetacaine Spray is indicated for use to control pain or gagging. Cetacaine in all forms is indicated to control pain and for use for surgical or endoscopic or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. It may also be used for vaginal or rectal procedures when feasible."],"drug_interactions_table":["
ClassExamples
Nitrates/Nitritesnitroglycerin, nitroprusside, nitric oxide, nitrous oxide
Local anestheticsbenzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine
Antineoplastic agentscyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea
Antibioticsdapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid
Antimalarialschloroquine, primaquine
Anticonvulsantsphenytoin, sodium valproate, phenobarbital
Other drugsacetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine
"],"information_for_patients":["PATIENT COUNSELING INFORMATION Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue. Hypersensitivity Reactions Unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. Localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. The most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. This occurs most commonly in patients following prolonged self-medication, which is contraindicated. If rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. To minimize the possibility of a serious allergic reaction, Cetacaine preparations should not be applied for prolonged periods except under continual supervision. Dehydration of the epithelium or an escharotic effect may also result from prolonged contact. Use in Pregnancy Safe use of Cetacaine has not been established with respect to possible adverse effects upon fetal development. Therefore, Cetacaine should not be used during early pregnancy, unless in the judgement of a physician, the potential benefits outweigh the unknown hazards. Routine precaution for the use of any topical anesthetic should be observed when Cetacaine is used."],"spl_unclassified_section":["In a bland, water-soluble base. Active ingredients Benzocaine 14.0% Butamben 2.0% Tetracaine Hydrochloride 2.0% Contains Benzalkonium Chloride 0.5% Cetyl Dimethyl Ethyl Ammonium Bromide 0.005%","Rx Only.","Autoclavable Cannula for Cetacaine Spray The supplied 4\" stainless steel cannula for Cetacaine Spray is specially designed for accessibility and application of Cetacaine, at the required site of pain control. Replacement cannulas are available as a 10-pack (Item # 0205).","Luer-lock Syringes and Microcapillary Delivery Tips for Cetacaine Liquid Cetacaine Liquid Syringes and Microcapillary Delivery Tips are supplied with the Cetacaine Liquid Chairside Kit (Item # 0218) and Clinical Kit (Item # 0212). They also can be purchased separately. Syringes are available in packs of 50 (Item # 0219S) or packs of 100 (Item # 0214). Delivery Tips are available in packs of 50 (Item # 0219T) or packs of 100 (Item # 0213).","Made in USA Cetylite Industries, Inc. Pennsauken, NJ 08110 Rev. 10 /18 www.cetylite.com"],"dosage_and_administration":["Dosage and Administration Cetacaine Spray should be applied for approximately one second or less for normal anesthesia. Only a limited quantity of Cetacaine is required for anesthesia. Spray in excess of two seconds is contraindicated. Each one-second spray contains an average of 200 mg of product, not including propellant. To apply, insert the cannula firmly onto the protruding plastic stem on the bottle and press the cannula forward to actuate the spray valve. The cannula may be removed and reinserted as many times as required for cleaning, or sterilization, and is autoclavable. Cetacaine Liquid Apply 200 mg liquid (approximately 0.2 mL) directly to tissue. Liquid in excess of 400 mg (approximately 0.4 mL) is contraindicated. To apply, remove and discard the shipping cap from the bottle. Replace it with the supplied Luer-lock cap. Caution: Do not over-tighten. Remove small cap from luer-lock port, retaining it for replacement after use. Port allows for a single dip of a cotton or brush applicator for application directly to accessible mucous membrane. For application into periodontal pockets, Cetylite Luer-lock syringes and Microcapillary Delivery Tips are recommended. Cetylite Syringes are clearly marked in (4) 0.1 mL increments. To fill, attach syringe to port by gently twisting clockwise until secure. Invert and draw desired amount of liquid into the syringe. Remove filled syringe and attach Microcapillary Delivery Tip to the syringe. Tip may be bent to improve access. Apply drop-wise to accessible mucous membrane (such as buccal and lingual sulcus) by slowly depressing the syringe plunger. Discard all applicators after use. An appropriate pediatric dosage has not been established for Cetacaine Spray or Cetacaine Liquid. Dosages should be reduced in the debilitated elderly, acutely ill, and very young patients (i.e., children 2 years and older). Do not use Cetacaine Spray or Cetacaine Liquid to treat infants or children younger than 2 years. Tissue need not be dried prior to application of Cetacaine. Cetacaine should be applied directly to the site where pain control is required. Anesthesia is produced within one minute with an approximate duration of thirty minutes. Each 200 mg dose of Cetacaine (Spray or Liquid) contains 28 mg of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCl."],"spl_product_data_elements":["Cetacaine Anesthetic Benzocaine, Butamben, and Tetracaine Hydrochloride Benzocaine Benzocaine Butamben Butamben Tetracaine Hydrochloride Tetracaine Dipropylene glycol Saccharin Benzalkonium chloride Mecetronium Bromide Cetacaine Anesthetic Benzocaine, Butamben, and Tetracaine Hydrochloride Benzocaine Benzocaine Butamben Butamben Tetracaine Hydrochloride Tetracaine Dipropylene glycol Saccharin Benzalkonium chloride Mecetronium Bromide Cetacaine Anesthetic Benzocaine, Butamben, and Tetracaine Hydrochloride Benzocaine Benzocaine Butamben Butamben Tetracaine Hydrochloride Tetracaine Dipropylene glycol Saccharin Benzalkonium chloride Mecetronium Bromide"],"spl_unclassified_section_table":["
In a bland, water-soluble base.
Active ingredients
Benzocaine14.0%
Butamben2.0%
Tetracaine Hydrochloride2.0%
Contains
Benzalkonium Chloride0.5%
Cetyl Dimethyl Ethyl Ammonium Bromide0.005%
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 11 g Bottle Box NDC 10223-0202-7 Item No. 0223 Cetacaine ® Topical Anesthetic LIQUID With Luer-lock Dispenser Cap 11g Control Pain Effective Only on Mucous Membrane CETYLITE ® PRINCIPAL DISPLAY PANEL - 11 g Bottle Box","PRINCIPAL DISPLAY PANEL - 24 g Bottle Box NDC 10223-0202-8 Item No. 0224 Cetacaine ® Topical Anesthetic LIQUID With Luer-lock Dispenser Cap 24g Control Pain Effective Only on Mucous Membrane CETYLITE ® PRINCIPAL DISPLAY PANEL - 24 g Bottle Box","PRINCIPAL DISPLAY PANEL - 11 g Bottle Kit OPEN HERE Cetacaine ® Topical Anesthetic LIQUID (Benzocaine 14.0%, Butamben 2.0%, and Tetracaine Hydrochloride 2.0%) Chairside Kit CETYLITE ® PRINCIPAL DISPLAY PANEL - 11 g Bottle Kit","PRINCIPAL DISPLAY PANEL - 24 g Bottle Kit NDC 10223-0226-1 ITEM NO: 0226 Cetacaine ® TOPICAL ANESTHETIC LIQUID CLINICAL KIT (Benzocaine 14.0%, Butamben 2.0%, and Tetracaine HCl 2.0%) Featuring a Unique Dispenser Cap for Accurate Filling of Luer-lock Syringes KIT CONTAINS: 1 24g bottle of Cetacaine Liquid 1 Luer-lock dispenser cap 100 Microcapillary Delivery Tips 100 Delivery Syringes CETYLITE ® Rx Only CAUTION: Not for injection. Do not use on the eyes. Keep out of reach of children. PRINCIPAL DISPLAY PANEL - 24 g Bottle Kit"]},"tags":[{"label":"butamben","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Topical","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Gel","category":"form"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"},{"label":"Itching of skin","category":"indication"},{"label":"Minor Skin Wound Pain","category":"indication"},{"label":"Skin irritation","category":"indication"},{"label":"Anesthetics","category":"pharmacology"},{"label":"Anesthetics, Local","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"METHAEMOGLOBINAEMIA","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"HYPOXIA","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"4 reports"},{"date":"","signal":"OXYGEN SATURATION DECREASED","source":"FDA FAERS","actionTaken":"4 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"3 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"CYANOSIS","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"RENAL INJURY","source":"FDA FAERS","actionTaken":"2 reports"}],"commonSideEffects":[],"contraindications":["Conduction disorder of the heart","Decreased respiratory function","Denuded skin","Open wound","Seizure disorder"],"specialPopulations":{"Pregnancy":"Use in Pregnancy: Safe use of One Touch Advanced Gel has not beenestablished with respect to possible adverse effects upon fetal development.Therefore, OneTouch Advanced Gel should not be used during early pregnancy,unless in the judgement of physician, the potential benefits outweigh the un--known hazards. Routine precaution for the use of any topical anesthetic shouldbe observed when OneTouch Advanced Gel is used."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BUTAMBEN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:59:44.287739+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:59:49.841765+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTAMBEN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:59:50.167314+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:59:43.027496+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:59:43.027524+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:59:43.027530+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:59:51.718639+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Transient receptor potential cation channel subfamily A member 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:59:51.216234+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL127516/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:59:50.868742+00:00"}},"allNames":"butesin","offLabel":[],"synonyms":["butamben","butambene","butesin","butesine","butoform","butyl 4-aminobenzoate","butylcaine"],"timeline":[],"brandName":"Butesin","ecosystem":[{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Minor Skin Wound Pain","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"benzethonium","slug":"benzethonium","company":""}],"globalPrevalence":null},{"indication":"Skin irritation","otherDrugs":[{"name":"allantoin","slug":"allantoin","company":""},{"name":"aluminum acetate","slug":"aluminum-acetate","company":"Bayer Pharms"},{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"benzethonium","slug":"benzethonium","company":""}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"Standardized Chemical Allergen [EPC]","explanation":"ActionThe onset of OneTouch Advanced-produced anesthesia is rapid (approximately30 seconds) and the duration of anesthesia is typically 30-60 minutes, whenused as directed. This effect is due to the rapid onset, but short duration ofaction of Benzocaine coupled with the slow onset, but extended duration ofTetracaine HCI and bridged by the intermediate action of Butamben.It is believed that all of these agents act by reversibly blocking nerve conduc--tion. Speed and duration of action is determined by the ability of the agent tobe absorbed by the mucous membrane and nerve sheath and then to diffuseout, and ultimately be metabolized (primarily by plasma cholinesterases) to inertmetabolites which are excreted in the urine.","oneSentence":"Butesin works by interacting with the nervous system to reduce pain and itching sensations.","technicalDetail":"Butesin is a butamben, a class of small molecule compounds that act as topical anesthetics by blocking sodium channels in nerve cells, thereby inhibiting the transmission of pain and itching signals to the brain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3051","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BUTAMBEN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTAMBEN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:06:13.197116","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:59:54.267888+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"butamben","indications":{"approved":[{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Minor Skin Wound Pain","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Skin irritation","source":"DrugCentral","snomedId":367466007,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06823544","phase":"PHASE2","title":"A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis.","status":"NOT_YET_RECRUITING","sponsor":"HITEC-Institute of Medical Sciences","startDate":"2025-02-01","conditions":["Alveolar Osteitis"],"enrollment":40,"completionDate":"2025-08-31"},{"nctId":"NCT06456060","phase":"PHASE1","title":"Efficacy of Pure Honey Dressing in Contrast to Alvogyl in the Resolution of Dry Socket","status":"RECRUITING","sponsor":"Watim Medical & Dental College","startDate":"2024-06-01","conditions":["Dry Socket"],"enrollment":40,"completionDate":"2025-01-30"},{"nctId":"NCT06144983","phase":"PHASE4","title":"Chlorhexidine Gel Versus Alvogyl Following Surgical Extraction of Impacted Mandibular Third Molar","status":"COMPLETED","sponsor":"University of Baghdad","startDate":"2022-02-01","conditions":["Impacted Third Molar Tooth"],"enrollment":51,"completionDate":"2022-09-01"},{"nctId":"NCT05814003","phase":"NA","title":"Clinical Effectiveness of Polymethoxy Flavones Solid Dispersion as a Dressing Material for Palatal Grafts Donor Sites","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-04-20","conditions":["Soft Tissue Infections","Gingival Recession"],"enrollment":30,"completionDate":"2023-05-20"},{"nctId":"NCT05334745","phase":"PHASE1","title":"Clinical Comparison of Topical Application of Alvogyl Versus Hyaluronic-Acid Gel in Management of Pain And Palatal Wound Healing","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-12-01","conditions":["Wound Healing"],"enrollment":16,"completionDate":"2023-01-01"},{"nctId":"NCT03402321","phase":"PHASE4","title":"Alveogyl and Gelatin Sponge in the Management of Pain After Epithelialized Free Gingival Graft Harvesting","status":"UNKNOWN","sponsor":"Karim ehab gerges","startDate":"2019-04-01","conditions":["Pain, Procedural"],"enrollment":36,"completionDate":"2019-07-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Aerosol, Gel, Solution","formulations":[{"form":"AEROSOL, SPRAY","route":"TOPICAL","productName":"Cetacaine Anesthetic"},{"form":"GEL","route":"TOPICAL","productName":"Cetacaine Topical Anesthetic"},{"form":"GEL","route":"TOPICAL","productName":"ONE TOUCH ADVANCED TOPICAL ANESTHETIC GELCOOL MINT"},{"form":"GEL","route":"TOPICAL","productName":"ONE TOUCH ADVANCED TOPICAL ANESTHETICBUBBLE GUM"},{"form":"GEL","route":"TOPICAL","productName":"ONE TOUCH ADVANCED TOPICAL ANESTHETICCHERRY"},{"form":"GEL","route":"TOPICAL","productName":"ONE TOUCH ADVANCED TOPICAL ANESTHETICSTRAWBERRY ICE"},{"form":"SOLUTION","route":"TOPICAL","productName":"Cetacaine Anesthetic"}]},"crossReferences":{"NUI":"N0000147741","MMSL":"14814","NDDF":"001368","UNII":"EFW857872Q","VUID":"4019648","CHEBI":"CHEBI:3231","VANDF":"4019648","RXNORM":"19861","UMLSCUI":"C0054235","chemblId":"CHEMBL127516","ChEMBL_ID":"CHEMBL127516","KEGG_DRUG":"D00730","DRUGBANK_ID":"DB11148","PUBCHEM_CID":"2482","SNOMEDCT_US":"108929004","MESH_SUPPLEMENTAL_RECORD_UI":"C004605"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":40,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jun 17","pmid":"40465558","title":"Engaging hydrazine hydrate as a hydrogen source for cobalt(II)-catalysed transfer hydrogenation of nitroaromatics.","journal":"Chemical communications (Cambridge, England)"},{"date":"2024 Dec 26","pmid":"39725929","title":"Evaluating the effectiveness of advanced platelet-rich fibrin, photobiomodulation, pentoxifylline, and Alveogyl in the treatment of alveolar osteitis: a randomized controlled clinical trial.","journal":"BMC oral health"},{"date":"2025 Jan 1","pmid":"39582403","title":"Novel topical dressing for dry socket and comparison of its efficacy with that of Alvogyl®: A randomized controlled clinical trial.","journal":"Medicina oral, patologia oral y cirugia bucal"},{"date":"2024 Nov 12","pmid":"39530606","title":"Low-level laser treatment's ability to reduce dry socket pain.","journal":"Acta odontologica Scandinavica"},{"date":"2024 Jun 27","pmid":"39065560","title":"Development of a Versatile Nanostructured Lipid Carrier (NLC) Using Design of Experiments (DoE)-Part II: Incorporation and Stability of Butamben with Different Surfactants.","journal":"Pharmaceutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:59:54.267888+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}